Pressmeddelanden • Sep 29, 2020 08:35 CEST
Umeå-based Lipigon has signed agreements with universities in Shanghai and Shenzhen to develop a new drug that can potentially reduce the number of deaths linked to Covid-19. “Right now there are very few treatments available for ARDS, which can be fatal to some Covid-19 patients. The standard treatment is oxygen and the use of respirators. We hope to change that,” says CEO, Stefan K Nilsson.